Relay Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 83.5 million compared to USD 67.5 million a year ago. Basic loss per share from continuing operations was USD 0.67 compared to USD 0.56 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.51 USD | -3.41% | -2.25% | -40.87% |
05-06 | Oppenheimer Adjusts Relay Therapeutics Price Target to $25 From $33, Maintains Outperform Rating | MT |
05-02 | Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q1 Revenue $10M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.87% | 864M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- RLAY Stock
- News Relay Therapeutics, Inc.
- Relay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023